The global market for stents in the treatment coronary artery disease, while dominated by drug-eluting stents, continues to also be comprised of a diversity of stent technologies. The market is evolving steadily as manufacturers aggressively seek optimal anti-restenosis, characterized by the goal of low rates of repeat revascularization. As with many medical technologies, prices, availability [...]
Coronary stent technology development trends include the stimulation of vessel wall healing following revascularization. OrbusNeich has developed its "Genous", a patented endothelial progenitor cell (EPC) capture technology designed and shown to promote the accelerated natural healing of the vessel wall following stenting. See link on OrbusNeich Genous recent data. The MedMarket Diligence report #C245 [...]
Translation: Drug-eluting stents are to bare metal stents as bare metal stents were to percutaneous transluminal coronary angioplasty alone. In the September 1 post on the meta-analysis by researchers at Tuft Medical Center, we noted the overall findings in general terms of the value of drug-eluting stents compared to bare metal stents. It is worthwhile to [...]
The global coronary stent market faces continued growth, development and competition from a wide range of technology types and competitors. The market is detailed in a new report from MedMarket Diligence. FOR IMMEDIATE RELEASE PRLog (Press Release) – Aug 31, 2009 – Since the advent of coronary stents, followed by the emergence of drug eluting [...]
In a report published in MedLink Neurology, Dr. Jose Biller of Loyola University Chicago’s Stritch School of Medicine completed a comprehensive review and compilation of previously published clinical studies on the possible neurological complications of heart surgery (Neurological complications of heart surgery). A range of difference potential complications have long been known to be attributable to heart [...]
In spite of arguments contesting whether bare metal or drug-eluting stents perform better, drug-eluting stents are here to stay and are still used in the majority of stent implantations. In fact, a plethora of studies have shown that DES can improve mortality rates and reduce the need for target vessel revascularization (TVR) compared with BMS. [...]
Stent manufacturer, Xtent, Inc., announced on Monday, August 3, that its shareholders had approved the plan to dissolve the company and liquidate. With the dissolution originally announced in May, the company appeared poised for a comeback when its Custom NX stent received conditional IDE approval from the FDA in June. The hope was that the approval [...]
The market for coronary stents is, in many ways, still emerging. While coronary stents have been on the commercial market in one form or another for several years, the technologies and materials used to create the devices are improving every day. In addition, innovative technology is bringing new classes of devices (e.g., fully degradable stents) [...]
While coronary stents have been classed into the orginal bare metal stents, the now dominant drug-eluting stents and the soon-to-emerge bioabsorbable stents, a range of other novel stent technologys are in development by companies seeking to established a clinical and competitive advantage in the treatment of coronary artery disease. Below are specific stent technologies under [...]
In cardiovascular and spine surgery, multi-billion dollar markets were created from entirely new procedures between 1980 and 2000, with subsequent segmentation in later years particularly as new minimally invasive procedures were developed towards the end of the 20th century. In the cardiovascular arena, the development of new procedures for angioplasty and bypasses in the late [...]
Contact:
